SX ELLA Esophageal Degradable BD Stent System

NACompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

January 31, 2015

Conditions
Benign Esophageal Lesions
Interventions
DEVICE

Stenting with ELLA Biodegradable stent

Treating benign esophageal lesions with the placement of a degradable stent

PROCEDURE

Standard Dilations

Treating benign esophageal lesions with standard dilation therapy

Trial Locations (8)

1000

Clinique Universitaire Saint Luc, Brussels

3000

University Hospitals Leuven, Leuven

3508

University Medical Center Utrech, Utrecht

13005

Hospital General Universitario de Ciudad Real, Ciudad Real

20089

IRCCS Istituto Clinico Humanitas, Milan

22700

Academic Medical Center, Amsterdam

Unknown

St. Antonius Hospital, Nieuwegein

NW1 2PG

University College of London Hospital, London

All Listed Sponsors
lead

Cook Group Incorporated

INDUSTRY

NCT01337206 - SX ELLA Esophageal Degradable BD Stent System | Biotech Hunter | Biotech Hunter